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ABSTRACT

Objective: The objective of this selective EBM review is to determine whether or not “Do oral
probiotics in conjunction with fluconazole reduce symptoms among patients suffering from
vulvovaginal candidiasis (VVC)?”
Study design: Systematic review of three randomized controlled trials published in 2009 and
2012.
Data sources: Three randomized controlled trials published in peer-reviewed journals comparing
the effects of fluconazole in conjunction with probiotics in the treatment of VVC. Data sources
found using Embase, EMBScohost, and CINAHL
Outcomes measured: Outcomes were measured based on patients reporting of: decrease in
dysuria symptoms at 5-7 days post treatment, resolution of abnormal odorless cheese like vaginal
discharge, dyspareunia, dysuria, and localized vulvovaginal irritation with VVC at 7 days post
treatment, and decrease in vaginal discharges associated with at least one of the following
(itching and burning vaginal feeling, dyspareunia and dysuria) at 4 weeks post treatment. All
results were examined to determine whether or not oral probiotics in conjunction with
fluconazole resulting in a significant difference in symptom reduction of VVC.
Results: In both Nouraei et al. and Martinez et al., oral probiotics in conjunction with fluconazole
showed a statistically significant different and proved to be an effective treatment in reducing the
symptoms associated with VVC (p= 0.02 and 0.03 respectively). Due to issue faced by the study
design in the RCT by Anukam et al., a statistically significant difference was unable to be found
when determining a reduction of VVC symptom (p=0.28).
Conclusions: Results of these RCT showed conflicting results. While both Nouraei et al. and
Martinez et al. indicated that oral probiotics in conjunction with fluconazole was an effective
treatment in the reduction of VVC symptoms Anukam et al. was unable to show a statistically
significant difference due to loss of follow up. Further studies with more strict protocol and a
larger sample size need to be explored in the future in order to reach more definitive answers.
Keywords: Vulvovaginal Candidiasis; Probiotics; Fluconazole
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INTRODUCTION
Vulvovaginal candidiasis (VVC) is a vaginal infection caused by the overgrowth of
naturally occurring Candida species due to a fluctuation in the normal environment and flora of
the vagina.1 Probiotics are supplements containing living microorganisms which are naturally
found in the body.2 It is thought that the use of these products may be beneficial in restoring the
body’s natural environment to base line. This systematic review evaluates three double blind,
randomized, controlled trials comparing the efficacy of oral probiotic use in combination with
fluconazole for the treatment of VVC in comparison to those being treated with fluconazole
alone.
With the high incidence of VVC it is important that physician assistants have a firm
understanding of this disorder and functional treatment methods to provide the best patient
outcomes. Statistics show that 75% of women suffer from VVC at least once during their lives,
45% of those women experience VVC twice or more annually and 5% are diagnosed with
chronic and recurrent infections.2 Recurrent VVC is defined as >4 episodes of VVC in a 12
month period.3
Diagnosis and treatment of VVC in addition to the lost wages accrued by decreased work
productivity resulted in a total cost of around $1.8 billion in 1995 and rose to $3.1 billion in
2014.4 While an exact estimate pertaining to VVC alone is not available, it has been determined
that roughly 5 to 10 million office visits per year are attributed to vaginitis.5 With VVC being
the second most common documented cause of vaginitis, after bacterial vaginosis,4 one can
imagine this number is quite high.
There are several etiological variations of Candida which result in VVC. 80-90% of cases
have been found to be due to Candida albicans, 5-15% are due to Candida glabrata,2 and a small
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percentage are due to Candida tropicalis.5 The overgrowth of these Candida species results in
varying symptoms including: thick, white, vaginal discharge, vulvovaginal itching, burning, and
dysuria.4
Standard treatment of symptomatic disease includes either oral medications or topical
vaginal suppositories and creams. For women with infrequent VVC, over the counter
preparations of miconazole or clotrimazole for 3-10 days are first line treatment.5 Although
topical treatments have traditionally been first line treatment, they are slightly hindered by
decreased compliance due to longer treatment courses and the discomfort caused by the manner
in which they are absorbed.1 Based on this, oral treatment with fluconazole 150 mg PO for 1 day
5

is becoming increasingly more common. Azole antifungal medications have been proven to

relieve symptoms and result in a negative culture in 80-90% of cases.1 The use of oral probiotics
in conjunction with tradition treatment methods, like fluconazole, may be used to reduce the
symptoms associated with VVC and increase the effectiveness of antifungal treatment.
Researchers believe that VVC and its traditional forms of treatment may lead to a
destruction of existing vaginal flora.2,4 This may result in prolonged symptoms and secondary
opportunistic vaginal infections. Due to the known benefits of probiotics, it is thought that they
may be quite valuable in the treatment of VVC. Previous studies have proven the benefit of
intravaginal probiotic usage in the prevention of VVC and other vaginal infections by
strengthening the natural vaginal flora.2 Lactobacillus and Bifidobacterium are two prevalent
microorganisms within the vaginal and are the focus of many probiotic treatments. Due to the
high incidence of VVC and frequent use of traditional treatments, oral probiotics are being
proposed as an adjunctive measure to treating VVC in a hope to improve the therapeutic
efficacy.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Do oral
probiotics in conjunction with fluconazole reduce symptoms among patients suffering from
vulvovaginal candidiasis (VVC)?”
METHODS
Three randomized, double blind, placebo controlled clinical trials with specific
population, intervention, comparison, and outcomes were selected for this systematic review. All
studies focused on a population of non-pregnant women diagnosed with symptomatic VVC. The
intervention which was studies was the use of oral probiotics in combination with fluconazole in
comparison to the use of a placebo pill in combination with fluconazole. These variants were
used to measure the outcome of reduced symptoms associated with VVC.
All articles were published in English written peer-reviewed journals and found by
myself using the Embase, EBScohost, and CINAHL databases. All studied were discovered
using the keywords “vulvovaginal candidiasis”, “probiotics” and “fluconazole”. All studies were
selected based on their relevance to the topic and whether or not they included patient oriented
evidence that matters (POEMs). The inclusion criteria used for this review were RCTs published
after 2007 that discussed the efficacy of oral probiotics in combination with fluconazole as a
treatment method for VVC. Exclusion criteria included pregnant patients suffering from VVC as
well as patients suffering from a combination of vaginal infections at the same time as a VVC
infection. The statistical significance of the study outcomes were determined using relative
benefit increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT), number
needed to harm (NNH) and p- value. The specific studies demographics and characteristics are
outlined in Table 1.
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TABLE 1: Demographics and characteristics of included studies
Study

Type

# Pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

W/
D

Intervention

Nouraei
(2012)2

RCT,
double
blind,
placebocontrolled

102

18-40

▪ women ages 18–
40
▪ married; in a
monogamous
relationship
▪ receiving
clotrimazole
without
improvement
▪ positive KOH
samples in culture
▪ diagnosed VVC
with itching,
cheesy vaginal
discharge, dysuria,
pH <4.5,
dyspareunia, vulvar
erythema, or vulvar
edema

▪ pregnant,
lactating, or
menstruating
▪ using any vaginal
medication,
antibiotics,
immunosuppressive
drugs, or exogenous
hormones during
the 2 weeks prior to
the study
▪intercourse or
vaginal douche in
the previous 24 hr
▪ positive
trichomonal or
bacterial vaginosis
infections
▪ known systemic
disease

12

Treatment of
vulvovaginal
candidiasis
with a
combination of
fluconazole
and oral
Protexin for 10
days

Anukam
(2009)3

RCT,
double
blind,
placebocontrol

59

18-50

▪ Women between
18-50
▪History of VVC
with >3 episodes
over the previous
12 months
▪symptomatic at
presentation

▪ Women with
evidence of other
urogenital
infections
▪ pregnant women

33

Lactobacillus
rhamnosus
GR-1 and
Lactobacillus
reuteri RC-14
with
fluconazole
treatment for 3
months

Martinez
(2009)4

RCT,
double
blinded,
placebocontrolled

55

16-46

▪ Women suffering
from vaginal
discharge
associated itching
and burning,
dyspareunia or
dysuria
▪ Positive Candida
culture

▪ Pregnant or
menstruating
▪ Positive for HIV,
BV, or
trichomoniasis
▪ Use of antibiotic/
anti-fungal agents
within 2 weeks
▪ fluconazole
allergy

Fluconazole
with two
probiotic
capsules
(containing
Lactobacillus
rhamnosus
GR-1 &
Lactobacillus
reuteri RC-14)
for 4 weeks
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OUTCOMES MEASURED
All selected RCT examined the effectiveness of oral probiotics in conjunction with
fluconazole in the treatment of VVC by measuring a reduction in reported symptoms. This
systematic review evaluates the outcomes that matter to patients in each RCT.
In all three RCT participants improvement was measuring based on patients subjective
impression and their reporting of a decrease in symptoms.
Study outcomes in the RCT by Nouraei et al. were measured 5-7 days after the start of
treatment based on patient reporting reduced dysuria associated with VVC when comparing the
fluconazole + placebo group to the fluconazole + protexin group.

Anukam et al. focuses on the resolution of symptoms by day 7 of treatment through the
use of a questionnaire which asked participants to log the day on which they obtained symptom
relief. Symptoms in this study were defined as abnormal, odorless, vaginal discharge,
dyspareunia, dysuria, and localized irritation or discomfort to the vulvovaginal area.
Martinez et al. measured resolution of vaginal discharge associated with at least one of
the following symptoms: dyspareunia, dysuria and itching or burning vaginal sensation on day
28 of treatment based on patient report.
RESULTS
This systematic review examined three RCT comparing the effectiveness of oral
probiotics in conjunction with fluconazole in the treatment of VVC. Each RCT studied nonpregnant women suffering from symptomatic VVC who had not been diagnosed with any other
vaginal infection. Specific inclusion and exclusion criteria are outlined in Table 1. All three
studies compared a placebo control to an oral probiotic group. The probiotic used in the RCT by
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Nouraei et al. was protexin. Anukam et al. and Martinez et al. both used Lactobacillus
rhamnosus GR-1 and Lactobacillus reuteri RC- 14 as the probiotics treatment. All three studies
contained dichotomous data that could be used to calculate RBI, ABI, and NNT.
In the RCT by Nouraei et al., 90 women who had been diagnosed with VVC were
randomly assigned to either the fluconazole + placebo group (n= 45) or the fluconazole +
protexin group (n= 45) to determine the effectiveness of oral probiotics in conjunction with
fluconazole in the treatment of VVC symptoms. Patients received two 150 mg fluconazole and
twenty placebo or protexin capsules, depending on their assigned group. Two protexin or
placebo capsules were administered per day, one in the morning and one in the evening, after
meals. Medications were distributed in a double-blinded manner. On days 5-7 after the start of
treatment patients were reevaluated for cure rate. Of the expressed symptoms (itching, cheesy
vaginal discharge, dysuria, dyspareunia, vulvar erythema and edema), a significant difference in
the reduction of dysuria symptoms (P = 0.02) were found. The fluconazole-protexin combination
proved to be more effective in the treatment of VVC associated dysuria than the fluconazoleplacebo group. Relative benefit increase (RBI) was calculated to be 69.5% and absolute benefit
increase (ABI) was calculated to be 33.2% (Table 2). Numbers needed to treat (NNT) was
calculated to be 4 (Table 2), meaning that for every 4 patients with VVC who were treated with
fluconazole in combination with Protexin, 1 more will have a resolution in dysuria symptoms
than the control group. All patients who entered into the study successfully completed all
treatments and none were lost to follow up. While the majority of patients reported no adverse
drug reactions, 6.7% of the fluconazole + placebo group reported nausea associated with their
treatment.2 Number needed to harm (NNH) was calculated to be -15, meaning that for every 15
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patients treated with fluconazole + Protexin, one fewer patients will have side effects than
compared to the control group (Table 3).
In the study by Anukam et al., 59 women who had been diagnosed with acute VVC were
randomized into two groups based on age and previous history of VVC. One group received
fluconazole + placebo (n= 20) and the remaining received fluconazole + L. rhamnosus GR-1 and
L. reuteri RC-14 (n= 39) to determine to effectiveness of oral probiotics in combination with
fluconazole in the treatment of VVC symptoms. Patients received one 150mg oral dose of
fluconazole plus either a daily placebo capsule or a daily probiotic capsule consisting of 5 billion
L. rhamnosus GR-1 and L. reuteri RC-14 live organisms depending on their treatment group.3
Treatments were distributed in a double blinded manner for 3 months. Patients were reassessed
at day 7 to document proof of cure and continued to follow up at 1 month, 2 months, and 3
months to assess their status. At each visit symptoms and cure rate were assessed based on
patient answered questionnaires, which focused on the day the patient felt as though they
obtained relief of symptoms (day 1 to day 7) and report of any side effects or recurrent infections
during the 90 day study period, as well as 2 vaginal swabs that were tested for yeast
microscopically and by culture. The final vaginal swabs, taken at 3 months, were further
assessed using bacterial and fungal DNA extraction and species specific primers for PCR.
The results of this study were severely hindered by a lack of full compliance by the
subjects. At the conclusion of the study 56% of patients were lost to follow up. Of the original 59
patients, 47 reported on day 7 (33 in the probiotic group and 14 in the placebo) and only 26
patients returned on day 30 and 90 (19 in the probiotic group and 7 in the placebo group). All
results were calculated using the data collected on day 7 from the patients who remained in the
study on day 90. Unfortunately, due to challenges faced by the study design, the research was
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unable to show a significant reduction of symptoms between the placebo and probiotic group. On
day 7 of the study 47% of the probiotic group reported a resolution of symptoms as compared to
14% of the placebo group3 (p=0.2794). The data demonstrated a relative benefit increase (RBI)
of 231.5% and an absolute benefit increase of 33.1% (Table 2). The number needed to treat
(NNT) was 4, meaning that 4 patients needed to be treated with fluconazole + L. rhamnosus GR1 and L. reuteri RC-14 in order for 1 more patient to experience a resolution of VVC symptoms
(Table 2).
Of the patients who followed up for the extent of the study, few reported side effects of
treatment. While the reported symptoms could not be directly correlated to the treatments, a few
patients in each group reported a single episode of headache and nausea during the 90 day
treatment window.3 Because the exact number of patients who reported side effects was not
disclosed, a number needed to harm (NNH) statistic could not be calculated.
In the study Martinez et al., 55 women who had been diagnosed with VVC by a positive
Candida culture were randomly dived into two groups, the fluconazole + placebo (n= 26) and the
fluconazole + L. rhamnosus GR-1 and L. reuteri RC-14 (n=29), to determine to effectiveness of
oral probiotics in combination with fluconazole in decreasing the symptoms associated with
VVC. Participants received a single 150mg dose of fluconazole plus either 2 capsules of L.
rhamnosus GR-1 and L. reuteri RC-14 (each capsule containing 1 x109 viable cells4) or 2 placebo
pills, depending on their treatment group. Treatments were distributed every morning in a double
blinded manner for 28 days. Patients were reassessed at day 28 based on patient report of
symptom resolution. A statistically significant difference was seen between the two groups; 26
patients in the probiotic group (n= 29) reported resolution of vaginal discharge and at least one
symptom (itching, burning, dyspareunia, and dysuria) where as only 17 on the control group
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(n=26) reported a resolution of symptoms4 (p= 0.03). The dichotomous data in this study
displays a relative benefit increase (RBI) of 37.2% and an absolute benefit increase (ABI) of
24.3% (Table 2). The number needed to treat (NNT) was found to be 5 (Table 2), meaning that 5
patients with VVC need to be treated with Fluconazole + L. rhamnosus GR-1 and L. reuteri RC14 in order for 1 to have a relief from symptoms.
While side effects could not be directly correlated to any treatment methods within the
study, two subjects in the fluconazole- probiotic group reported an increase in appetite, one
reported a single episode of light stool and another reported one headache during treatment.4
Based on reported side effected the number needed to harm (NNH) is 8, meaning that for every 8
patients treated with Fluconazole + L. rhamnosus GR-1 and L. reuteri RC-14 , 1 more will
experience an adverse reaction than compared to the control group(See Table 3).
TABLE 2: Treatment effects
RCT
Nouraei (2012)
Anukam (2009)
Martinez (2009)

RBI
69.5%
231.5%
37.2%

ABI
33.2%
33.1%
24.3%

NNT
4
4
5

p-value
0.02
0.28
0.03

TABLE 3: Side effects
RCT
Nouraei (2012)
Martinez (2009)

CER
6.7%
0.0%

EER
0.0%
13.8%

RRI
-1
Error

ARI
-6.7
13.8%

Probiotic vs. Control
Control group
Probiotic group

NNH
-15
8

DISCUSSION
Traditionally VVC has been treated with oral azoles. However, recent studies have shown
that the addition of probiotics to treatment regiments may prove to be quite useful. Probiotics are
live microorganisms which are similar to those naturally found in the human body, and therefore
thought to be beneficial to human health.2 Lactobacilli species, such as L. rhamnosus and L.
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reuteri, can found within vaginal flora.2 Studies show that these probiotics play an important role
in suppressing potential vaginal pathogen.2
The studies in this systematic review analyze probiotic use in combination with
fluconazole in the treatment of VVC. Results were deemed significant based on symptom
reduction in the probiotic group when compared to the placebo group if the p value was shown to
be < 0.05. While two studies proved to have significant results, the study by Anukam et al. was
significant hindered by loss to follow up. After a 37% reduction in patient follow up at day 7,
and further reduction of 56% at day 90, the sample size proved too small to provide statistically
significant results limiting the validity of this study.
Although some studies have shown probiotics to hold significant benefit in certain health
conditions this has not been evaluated by the FDA and is therefore has not been approved as a
treatment in any disease.6
Due to the lack of FDA recognition, little research has been done regarding the side
effects and warnings associated with probiotics. As of now it is believed that they are relatively
harmless to healthy individuals and that the majority of patients do not suffer any side effects
associated with usage. But because little is known about the actual affects of probiotics it is
suggested that immunocompromised patients refrained from using probiotics.6
Because probiotics are not considered a treatment for disease approved by the FDA, few
health insurance plans are willing to cover the cost. Fortunately probiotics are relatively
inexpensive, averaging around $20 per bottle. Traditional fluconazole treatment tends to be
rather inexpensive as well, ranging from $4-12 on average.7 The low costs of these products
make treatment much more accessible to patients.
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CONCLUSION
Although the majority of the studies in this systematic review supported the proposed
hypothesis, the study by Anukam et al. was severely hindered by patient compliance and loss to
follow up. Due to personal hardships faced by these patients in their home country of Nigeria, it
proved difficult for this population to follow through with the study. The study suggested that
patients lacked a great understanding of the condition and the purpose of the study. For
significant results to be determined it is essential that larger studies with strict protocols and
extensive patient education be conducted in an attempt to prevent such poor results. Because of
this, it is necessary to say that results were inconclusive as to whether or not oral probiotics in
conjunction with fluconazole reduce symptoms among patients suffering from vulvovaginal
candidiasis.
Future study is warranted to test a wider variety of oral probiotics and determine their
effect in treating the symptoms of VVC. While all probiotics work in a similar manner, it is
important to clarify the treatment outcomes of each probiotic strain so that it is not assumed all
hold the same efficacy in VVC symptom reduction.
With the expansion of the medical field and the need for new treatments to battle the
rising rate of drug resistance it is likely that this topic will be further explored in future studies
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